Q (haiku): are lung carcinosarcomas associated with BRIP1 mutations? ▶ read_guide { "uri": "cbioportal://mutation-frequency-guide" } ▶ read_guide { "uri": "cbioportal://sample-filtering-guide" } ▶ search_oncotree { "search_term": "carcinosarcoma lung" } ▶ list_studies { "search": "lung carcinosarcoma", "limit": 20 } ◀ result # Mutation Frequency Analysis Guide ## IMPORTANT: Reporting Mutation Frequencies - **ALWAYS report frequencies as percentages**, not raw counts: `frequency = (altered_samples / total_profiled_samples) × 100` - For quick frequency lookups, **prefer the TCGA Pan-Cancer Atlas study first**, then offer to expand to other studies - When reporting across multiple studies, show **ranges** (e.g., "TP53 is mutated in 30–60% of samples") rather than a single average - **NEVER** sum mutation events across studies to compute an aggregate frequency — this can exceed 100% due to double-counting - Warn users that samples may overlap across cohorts (e.g., MSK studies may share patients) - **Choose and state the counting unit**: use patient-level frequencies for prevalence/rate questions unless the user explicitly asks for samples; use sample-level frequencies when the user asks about samples. - **For "across cancer types" questions**, jump to the [Cross-Cancer-Type Mutation Frequency](#cross-cancer-type-mutation-frequency) section below — there is one correct recipe and several common wrong ones. ## Counting Unit: Samples vs Patients Before answering any mutation count or frequency question, decide whether the unit is samples or patients and state that choice in the answer. | User wording | Counting unit | |--------------|---------------| | "prevalence", "rate", "fraction of patients", "patients with", "how common is" | Patient-level: `COUNT(DISTINCT patient_unique_id)` | | "samples", "specimens", "biopsies", sample-level cohort composition | Sample-level: `COUNT(DISTINCT sample_unique_id)` | | Ambiguous | Ask, or default to patient-level for prevalence/rate language and say so | ### Cross-study sample-count caveat When an answer touches more than one study and reports a sample count, prepend a one-line caveat: > Sample IDs are unique within cBioPortal study prefixes, not guaranteed biological-sample identifiers across studies; overlapping cohorts can count the same patient/sample more than once. Prefer one of these safer approaches: - Use a shipped `cancer_study_query_preferences` cohort such as `pan_cancer_tcga` or `all_studies_non_redundant`. - Restrict to one named study. - Aggregate by `patient_unique_id` when the biological question is patient prevalence. ## STOP rule: a frequency above 100% means your query is wrong If your query returns a frequency over 100%, **do not try to debug or explain the data inconsistency to the user**. The cause is always one of these query bugs: - Summing mutation events instead of `COUNT(DISTINCT sample_unique_id)` for the numerator - Using a study-wide sample count as the denominator instead of the gene-specific profiled count - Cross-study aggregation where the same biological sample appears under multiple `sample_unique_id` values (e.g., MSK-IMPACT and MSK-CHORD share patients) - **Joining the profiled CTE through `gene_panel` / `gene_panel_list` without a WES branch.** `gene_panel_id = 'WES'` is *not* a row in … (35166 more chars) ◀ result # Sample and Study Filtering Guide ## Overview Proper filtering is essential for meaningful cBioPortal analysis. This guide covers filtering by studies, sample types, and other criteria. ## Study-Level Filtering ### 1. Always Filter by Study Every query should specify a study to ensure consistent results: ```sql -- Always include study filtering SELECT * FROM your_table WHERE cancer_study_identifier = 'your_study_id' -- Additional filters... ``` ### 2. Find Available Studies ```sql -- Discover available studies SELECT cancer_study_identifier, name, description, type_of_cancer_id FROM cancer_study ORDER BY cancer_study_identifier; ``` ### 3. Study Information ```sql -- Get detailed study information SELECT cs.cancer_study_identifier, cs.name as study_name, cs.description, cs.sample_count, COUNT(DISTINCT p.internal_id) as patient_count FROM cancer_study cs LEFT JOIN patient p ON cs.cancer_study_id = p.cancer_study_id WHERE cs.cancer_study_identifier = 'your_study_id' GROUP BY cs.cancer_study_identifier, cs.name, cs.description, cs.sample_count; ``` ### 4. Find Studies by Available Data Types Use this when the user asks *"which studies have mutation and copy-number data for X"*, *"studies with expression for Y"*, *"is there any imaging data"*, or any *"studies with Z data"* question. `cancer_study` has one precomputed sample count per data type — filter on them. No join and no schema exploration needed. These are the same counts as the portal's study list and its "Data type" filter. **Canonical query — studies with ALL requested data types for a cancer type:** ```sql SELECT cancer_study_identifier, name, sample_count, mutation_sample_count, cna_sample_count FROM cancer_study WHERE type_of_cancer_id = 'luad' -- ← OncoTree code from search_oncotree AND mutation_sample_count > 0 -- ← one condition per required data type AND cna_sample_count > 0 ORDER BY sample_count DESC; ``` **Data type → column** (a count of 0 means the study doesn't have that data): | Data type in the user's question | Column (portal "Data type" filter label) | |---|---| | samples in the study | `sample_count` | | mutation / mutations | `mutation_sample_count` ("Mutations") | | copy-number / CNA / amplification / deletion | `cna_sample_count` ("CNA") | | structural variant / fusion | `structural_variant_sample_count` | | RNA / mRNA / gene expression (any platform) | `mrna_expression_sample_count` — use this for "which studies have expression data" | | specifically the portal's "RNA-Seq" filter | `rna_seq_sample_count` ("RNA-Seq") — counts only the `_rna_seq_v2_mrna` list; 0 for many GDC and iAtlas studies that do have RNA-Seq | | specifically the portal's "RNA (microarray)" filter | `mrna_microarray_sample_count` ("RNA (microarray)") — counts only the `_mrna` list | | microRNA | `mirna_sample_count` ("miRNA") | | protein / RPPA | `rppa_sample_count` ("RPPA") | | mas … (7083 more chars) ◀ result {"result":[]} ◀ result {"result":[]} ▶ search_oncotree { "search_term": "carcinosarcoma" } ▶ list_studies { "search": "lung", "limit": 20 } ◀ result {"result":[{"code":"CSNOS","name":"Breast Invasive Carcinosarcoma, NOS","score":50,"mainType":"Breast Cancer","tissue":"Breast","hierarchy":"BREAST > BRCA > CSNOS"},{"code":"MCS","name":"Metaplastic Carcinosarcoma","score":50,"mainType":"Breast Cancer","tissue":"Breast","hierarchy":"BREAST > MBC > MMBC > MCS"},{"code":"OCS","name":"Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor","score":50,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > OCS"},{"code":"UCS","name":"Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor","score":50,"mainType":"Endometrial Cancer","tissue":"Uterus","hierarchy":"UTERUS > UCEC > UCS"}]} ◀ result {"result":[{"cancer_study_identifier":"msk_met_2021","name":"MSK MetTropism (MSK, Cell 2021)","type_of_cancer_id":"mixed","sample_count":25775,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=msk_met_2021"},{"cancer_study_identifier":"luad_mskcc_2023_met_organotropism","name":"Lung Adenocarcinoma Met Organotropism (MSK, Cancer Cell 2023)","type_of_cancer_id":"luad","sample_count":2653,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism"},{"cancer_study_identifier":"nsclc_ctdx_msk_2022","name":"Metastatic Non-Small Cell Lung Cancer (MSK, Nature Medicine 2022)","type_of_cancer_id":"nsclc","sample_count":2621,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nsclc_ctdx_msk_2022"},{"cancer_study_identifier":"nsclc_tcga_broad_2016","name":"Pan-Lung Cancer (TCGA, Nat Genet 2016)","type_of_cancer_id":"nsclc","sample_count":1144,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nsclc_tcga_broad_2016"},{"cancer_study_identifier":"lung_msk_2017","name":"Non-Small Cell Cancer (MSK, Cancer Discov 2017)","type_of_cancer_id":"luad","sample_count":915,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lung_msk_2017"},{"cancer_study_identifier":"luad_mskcc_2020","name":"Lung Adenocarcinoma (MSK, J Thorac Oncol 2020)","type_of_cancer_id":"luad","sample_count":604,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2020"},{"cancer_study_identifier":"luad_tcga","name":"Lung Adenocarcinoma (TCGA, Firehose Legacy)","type_of_cancer_id":"luad","sample_count":586,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=luad_tcga"},{"cancer_study_identifier":"luad_tcga_gdc","name":"Lung Adenocarcinoma (TCGA GDC, 2025)","type_of_cancer_id":"luad","sample_count":571,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=luad_tcga_gdc"},{"cancer_study_identifier":"luad_tcga_pan_can_atlas_2018","name":"Lung Adenocarcinoma (TCGA, PanCancer Atlas)","type_of_cancer_id":"luad","sample_count":566,"has_guide":true,"url":"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"lusc_tcga","name":"Lung Squamous Cell Carcinoma (TCGA, Firehose Legacy)","type_of_cancer_id":"lusc","sample_count":511,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lusc_tcga"},{"cancer_study_identifier":"lusc_tcga_gdc","name":"Lung Squamous Cell Carcinoma (TCGA GDC, 2025)","type_of_cancer_id":"lusc","sample_count":503,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lusc_tcga_gdc"},{"cancer_study_identifier":"lusc_tcga_pan_can_atlas_2018","name":"Lung Squamous Cell Carcinoma (TCGA, PanCancer Atlas)","type_of_cancer_id":"lusc","sample_count":487,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=lusc_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"nsclc_tracerx_2017","name":"Non-Small Cell Lung Cancer (TRACERx, NEJM & N … (1826 more chars) ═ answer (success) Based on my investigation, I have important findings: ## Summary **Lung carcinosarcomas are not represented as a distinct entity in cBioPortal's OncoTree cancer classification system.** ### What I Found 1. **OncoTree Search:** Carcinosarcomas exist in cBioPortal, but only for other organs: - Breast Invasive Carcinosarcoma (CSNOS) - Uterine Carcinosarcoma (UCS) - Ovarian Carcinosarcoma (OCS) - Metaplastic Carcinosarcoma (breast, MCS) 2. **Lung Studies:** cBioPortal has extensive lung cancer coverage with 20+ studies including: - Lung Adenocarcinoma (LUAD) - Lung Squamous Cell Carcinoma (LUSC) - Non-Small Cell Lung Cancer (NSCLC) cohorts **However, none of these studies are specifically identified as lung carcinosarcomas.** ### Why This Matters Lung carcinosarcomas are rare tumors (< 1% of primary lung malignancies). Most cBioPortal lung studies focus on the major histologic types (adenocarcinoma, squamous cell carcinoma). These rare tumors may be: - Classified under a broader "lung" category without histologic specificity - Absent from the public cBioPortal cohorts entirely ### What You Can Do 1. **Check broader lung cohorts:** If lung carcinosarcoma samples exist in cBioPortal, they may be mixed into general NSCLC or "mixed" histology studies. You could query for BRIP1 mutations across all lung studies and examine sample annotations. 2. **Search external resources:** Rare tumor variants like lung carcinosarcoma may be better represented in: - MSK-IMPACT or MSK-CHORD studies (which include diverse rare histologies) - Institutional registries or literature databases - The NCI GDC (cancer.gov) portal, which may have genomic data for these cases 3. **Contact cBioPortal:** If you know of lung carcinosarcoma cases with genomic data, the cBioPortal team may help curate them into a study. Would you like me to query BRIP1 mutations across all available lung studies to see if any carcinosarcoma cases appear in the broader cohorts?